Comparative Analysis of Clinical Efficacy and Safety of Pyrotinib Plus Capecitabine versus Trastuzumab Emtansine (T-DM1) as Second-Line Treatment for HER2-Positive Advanced Breast Cancer: A Retrospective Study
Pyrotinib plus capecitabine significantly improves median PFS compared to T-DM1 in patients with HER2-positive advanced breast cancer, demonstrating a favorable efficacy profile alongside manageable safety concerns.
Authors
- Fenge Jiang
- Congcong Wang (ORCID: https://orcid.org/0000-0003-3947-2569)
- Ping Sun
- Hao Han
- Jiannan Liu
Institutions
- Yuhuangding Hospital (CN)
- Second Hospital of Shandong University (CN)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2025-04-01
- DOI
- https://doi.org/10.2147/dddt.s516394
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Natural Science Foundation of China